SynthesisJAMA otolaryngology-- head & neck surgery2025
Unilateral vs Bilateral Transoral Surgery for Tonsillar Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Synthesis in JAMA otolaryngology-- head & neck surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk-Stratified Bilateral Tonsillectomy for Unilateral HPV-Associated Tonsillar SCC: Oncologic and Functional Outcomes From a Single Institution.Laryngoscope investigative otolaryngology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Transoral surgery via a radical tonsillectomy followed by pathology-guided adjuvant therapy is standard of care for tonsillar squamous cell carcinoma (SCCa). There is significant variation in the management of the contralateral tonsil without clinical evidence of disease. Objective: To assess the second primary tumor rates, oncologic survival, functional outcomes, and complications between bilateral and unilateral transoral surgery for tonsillar SCCa. Data Sources: A search of Embase, Ovid MEDLINE, Scopus, and Cochrane was performed on September 11, 2024. Study Selection: Inclusion criteria were studies with more than 10 adults undergoing transoral surgery for unilateral tonsillar SCCa reporting at least 1 primary or secondary outcome. Screening of abstracts and full texts along with data extraction were performed in duplicate. Data Extraction and Synthesis: The Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guideline was followed. Data were pooled using a random-effects model. Main Outcomes and Measures: The primary outcome measure was the synchronous and metachronous contralateral tonsil second primary tumor rates. Secondary outcome measures were between-group differences in oropharyngeal hemorrhage and gastrostomy tube dependence rates and 2-year and 5-year overall survival (OS) and disease-free survival (DFS). Results: Of 136 unique citations identified, 11 studies were included, representing a total of 1486 patients (634 bilateral surgery, 852 unilateral surgery). The synchronous contralateral tonsil second primary tumor rate in the bilateral surgery group was 4.0% (95% CI, 2.0%-5.0%; I2 = 0.05%). The metachronous contralateral tonsil second primary tumor rate in the unilateral surgery group was 0.1% (95% CI, 0%-1%; I2 = 0.04%). There were no between-group differences in oropharyngeal bleeding rate (-0.2% [95% CI, -5.6% to 5.3%]) or gastrostomy tube dependence rate (-0.5% [95% CI, -5.2% to 4.3%]). The 2-year and 5-year pooled OS proportion differences between the bilateral surgery and unilateral surgery groups were 3.6% (95% CI, -2.2% to 9.4%) and 5.3% (95% CI, -3.8% to 14.4%), respectively. The 2-year and 5-year pooled DFS proportion differences between the bilateral surgery and unilateral surgery groups were -0.5% (95% CI, -6.5% to 5.4%) and 11.1% (95% CI, 1.6%-20.5%), respectively. Conclusions and Relevance: This systematic review and meta-analysis suggests that omission of contralateral elective extracapsular tonsillectomy in tonsillar SCCa is safe with markedly low metachronous contralateral tonsillar second primary tumor rates and no compromise in survival. The decision to perform a simultaneous contralateral extracapsular tonsillectomy can be addressed via clinician-patient shared decision-making with consideration of its pros and cons.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.